Bank of Nova Scotia
ANTX icon

Bank of Nova Scotia’s AN2 Therapeutics ANTX Stock Holding History

Bank of Nova Scotia’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-459,194
Closed -$1.57M – 1103
2026
Q1 		$1.57M Hold
459,194
– – ﹤0.01% 785
2025
Q4 		$523K Hold
459,194
– – ﹤0.01% 943
2025
Q3 		$583K Hold
459,194
– – ﹤0.01% 866
2025
Q2 		$487K Hold
459,194
– – ﹤0.01% 859
2025
Q1 		$625K Buy
459,194
+64,326
+16% +$81K ﹤0.01% 792
2024
Q4 		$545K Buy
+394,868
New +$479K ﹤0.01% 843

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Bank of Nova Scotia's ANTX Position: Q2 2026 in Review

Bank of Nova Scotia sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 459,194 shares — an estimated $1.57M sold.

Bank of Nova Scotia first reported a position in ANTX in Q4 2024 and held it in 6 quarters. The position peaked at $1.57M in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Bank of Nova Scotia reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 459,194 AN2 Therapeutics shares in Q2 2026, an estimated $1.57M.
  • Bank of Nova Scotia first reported a position in AN2 Therapeutics in Q4 2024 and held it in 6 quarters.
  • Bank of Nova Scotia's AN2 Therapeutics position peaked at $1.57M in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.